Protocol Ledger

NCT05707351 · Phase III · COMPLETED

A Study of Adynovate in Previously Treated Chinese Teenagers and Adults With Severe Hemophilia A

Interventional Phase III clinical trial protocol NCT05707351 sponsored by Takeda in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-03-27 Enrollment: 37 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05707351
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)37 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05707351
Protocol FieldVerified Registry Value
NCT IdentifierNCT05707351
Consolidated Lead SponsorTakeda
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment37 participants (ACTUAL)
Registered Start Date2023-03-27
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Takeda across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI